Imaging the Function of P‐Glycoprotein With Radiotracers: Pharmacokinetics and In Vivo Applications

[1]  Jeih-San Liow,et al.  Human Brain Imaging and Radiation Dosimetry of 11C-N-Desmethyl-Loperamide, a PET Radiotracer to Measure the Function of P-Glycoprotein , 2009, Journal of Nuclear Medicine.

[2]  F. Nelson,et al.  The Effect of Breast Cancer Resistance Protein and P-Glycoprotein on the Brain Penetration of Flavopiridol, Imatinib Mesylate (Gleevec), Prazosin, and 2-Methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic Acid (PF-407288) in Mice , 2009, Drug Metabolism and Disposition.

[3]  Yue Weng,et al.  Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding , 2009, Science.

[4]  K. Fukushi,et al.  Noninvasive and Quantitative Assessment of the Function of Multidrug Resistance-Associated Protein 1 in the Living Brain , 2009, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[5]  P. Herscovitch,et al.  P-Glycoprotein Function at the Blood–Brain Barrier Imaged Using 11C-N-Desmethyl-Loperamide in Monkeys , 2008, Journal of Nuclear Medicine.

[6]  S. Houle,et al.  The role of P-glycoprotein on blood brain barrier permeability of [11C]Loperamide in humans , 2008, NeuroImage.

[7]  U. B. Nair,et al.  Tariquidar, a Selective P-glycoprotein Inhibitor, Does Not Potentiate Loperamide’s Opioid Brain Effects in Humans despite Full Inhibition of Lymphocyte P-glycoprotein , 2008, Anesthesiology.

[8]  Jeih-San Liow,et al.  Synthesis and evaluation of [N-methyl-11C]N-desmethyl-loperamide as a new and improved PET radiotracer for imaging P-gp function. , 2008, Journal of medicinal chemistry.

[9]  M. Lubberink,et al.  Blood-brain barrier P-glycoprotein function is not impaired in early Parkinson's disease. , 2008, Parkinsonism & related disorders.

[10]  Heidrun Potschka,et al.  Seizure-Induced Up-Regulation of P-Glycoprotein at the Blood-Brain Barrier through Glutamate and Cyclooxygenase-2 Signaling , 2008, Molecular Pharmacology.

[11]  Jeih-San Liow,et al.  11C-Loperamide and Its N-Desmethyl Radiometabolite Are Avid Substrates for Brain Permeability-Glycoprotein Efflux , 2008, Journal of Nuclear Medicine.

[12]  M. Bermejo.  Faculty Opinions recommendation of Kinetic considerations for the quantitative assessment of efflux activity and inhibition: implications for understanding and predicting the effects of efflux inhibition. , 2008 .

[13]  K. Leenders,et al.  Decreased blood–brain barrier P-glycoprotein function in the progression of Parkinson’s disease, PSP and MSA , 2008, Journal of Neural Transmission.

[14]  S. Ambudkar,et al.  Development of inhibitors of ATP-binding cassette drug transporters – present status and challenges , 2008, Expert opinion on drug metabolism & toxicology.

[15]  S-F Zhou,et al.  Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. , 2008, Xenobiotica; the fate of foreign compounds in biological systems.

[16]  A. Calcagno,et al.  ABC drug transporters as molecular targets for the prevention of multidrug resistance and drug-drug interactions. , 2007, Current drug delivery.

[17]  Alexander Hammers,et al.  Pharmacoresistance in Epilepsy : A Pilot PET Study with the P-Glycoprotein Substrate R-[ 11 C ] verapamil ∗ † , 2007 .

[18]  A. Mangoni.  The impact of advancing age on P-glycoprotein expression and activity: current knowledge and future directions , 2007, Expert opinion on drug metabolism & toxicology.

[19]  R. P. Maguire,et al.  Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[20]  Elizabeth Fox,et al.  Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor , 2007, Expert review of anticancer therapy.

[21]  W. Löscher.  Drug Transporters in the Epileptic Brain , 2007, Epilepsia.

[22]  Mark Lubberink,et al.  Evaluation of Tracer Kinetic Models for Quantification of P-Glycoprotein Function using (R)-[11C]Verapamil and PET , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[23]  Lippincott-Schwartz,et al.  Supporting Online Material Materials and Methods Som Text Figs. S1 to S8 Table S1 Movies S1 to S3 a " Silent " Polymorphism in the Mdr1 Gene Changes Substrate Specificity Corrected 30 November 2007; See Last Page , 2022 .

[24]  G. M. Pollack,et al.  Kinetic Considerations for the Quantitative Assessment of Efflux Activity and Inhibition: Implications for Understanding and Predicting the Effects of Efflux Inhibition , 2007, Pharmaceutical Research.

[25]  D. Piwnica-Worms,et al.  Single photon emission computed tomography and positron emission tomography imaging of multi-drug resistant P-glycoprotein--monitoring a transport activity important in cancer, blood-brain barrier function and Alzheimer's disease. , 2006, Neuroimaging clinics of North America.

[26]  Yuichi Sugiyama,et al.  Quantitative analysis of 11C-verapamil transfer at the human blood-brain barrier for evaluation of P-glycoprotein function. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[27]  Yuichi Sugiyama,et al.  Evaluation of in vivo P-glycoprotein function at the blood-brain barrier among MDR1 gene polymorphisms by using 11C-verapamil. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[28]  R. Kim,et al.  Differential in Vivo Sensitivity to Inhibition of P-glycoprotein Located in Lymphocytes, Testes, and the Blood-Brain Barrier , 2006, Journal of Pharmacology and Experimental Therapeutics.

[29]  M. Gottesman,et al.  Targeting multidrug resistance in cancer , 2006, Nature Reviews Drug Discovery.

[30]  G. D'aiuto,et al.  In vivo detection of multidrug-resistant (MDR1) phenotype by technetium-99m sestamibi scan in untreated breast cancer patients , 1997, European Journal of Nuclear Medicine.

[31]  A. Fagan,et al.  P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. , 2005, The Journal of clinical investigation.

[32]  C. Baumgartner,et al.  Influence of functional haplotypes in the drug transporter gene ABCB1 on central nervous system drug distribution in humans , 2005, Clinical pharmacology and therapeutics.

[33]  D. Mankoff,et al.  Imaging P‐glycoprotein Transport Activity at the Human Blood‐brain Barrier with Positron Emission Tomography , 2005, Clinical pharmacology and therapeutics.

[34]  J. Bart,et al.  Blood–brain barrier dysfunction in parkinsonian midbrain in vivo , 2005, Annals of neurology.

[35]  Gert Luurtsema,et al.  Evaluation of (R)-[11C]verapamil as PET tracer of P-glycoprotein function in the blood-brain barrier: kinetics and metabolism in the rat. , 2005, Nuclear medicine and biology.

[36]  C. Baumgartner,et al.  Association of an ABCB1 gene haplotype with pharmacoresistance in temporal lobe epilepsy , 2004, Neurology.

[37]  I. Scheffer,et al.  Failure to confirm association of a polymorphism in ABCB1 with multidrug-resistant epilepsy , 2004, Neurology.

[38]  Joost Bart,et al.  PET Studies on P-glycoprotein function in the blood-brain barrier: how it affects uptake and binding of drugs within the CNS. , 2004, Current pharmaceutical design.

[39]  H. Kroemer,et al.  The role of P-glycoprotein in cerebral amyloid angiopathy; implications for the early pathogenesis of Alzheimer's disease. , 2004, Current Alzheimer research.

[40]  C. L. Graff,et al.  Drug transport at the blood-brain barrier and the choroid plexus. , 2004, Current drug metabolism.

[41]  M. Salvatore,et al.  MIBI as prognostic factor in breast cancer. , 2003, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[42]  T. Fojo,et al.  Increased 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[43]  J. Bading,et al.  Brain Clearance of Alzheimer's Amyloid-β40 in the Squirrel Monkey: A SPECT Study in a Primate Model of Cerebral Amyloid Angiopathy , 2002, Journal of drug targeting.

[44]  M. Gottesman,et al.  Multidrug resistance in cancer: role of ATP–dependent transporters , 2002, Nature Reviews Cancer.

[45]  M. Gottesman.  Mechanisms of cancer drug resistance. , 2002, Annual review of medicine.

[46]  D. Piwnica-Worms,et al.  Effects of MDR1 and MDR3 P-glycoproteins, MRP1, and BCRP/MXR/ABCP on the transport of (99m)Tc-tetrofosmin. , 2000, Biochemical pharmacology.

[47]  C. Higgins,et al.  The molecular interaction of the high affinity reversal agent XR9576 with P‐glycoprotein , 1999, British journal of pharmacology.

[48]  I. Pastan,et al.  Biochemical, cellular, and pharmacological aspects of the multidrug transporter. , 1999, Annual review of pharmacology and toxicology.

[49]  W Vaalburg,et al.  Complete in vivo reversal of P‐glycoprotein pump function in the blood‐brain barrier visualized with positron emission tomography , 1998, British journal of pharmacology.

[50]  T. Fojo,et al.  Detection of in vivo P-glycoprotein inhibition by PSC 833 using Tc-99m sestamibi. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[51]  Y. Sugiyama,et al.  Brain efflux index as a novel method of analyzing efflux transport at the blood-brain barrier. , 1996, The Journal of pharmacology and experimental therapeutics.